Słowa kluczowe
resveratrol
atherosclerosis
heart failure
obesity
Jak cytować
Abstrakt
Introduction and aim of the study. Cardiovascular disease (CVD) represents a significant global health concern. The potential benefits of molecules that have a positive impact on the cardiovascular system are still being investigated. The objective of this study is to conduct a comprehensive review of the existing literature and to evaluate the effect of polyphenols on a range of selected cardiovascular diseases.
Review methods. Relevant information was collected through a systematic search of PubMed and Google Scholar. The following search terms were used: “polyphenols,” “resveratrol,” “atherosclerosis,” “stroke,” “heart failure,” “hypertension,” “coronary artery disease,” “obesity.” The scientific articles subjected to analysis included meta-analyses and randomized clinical trials, presented in both Polish and English. A total of 44 scientific articles were analyzed, of which 41 were published after 2016. Current knowledge. Polyphenols are present in a multitude of commonly consumed and readily available products, including nuts, olive oil, fruits and vegetables, wine, and tea. The anti-inflammatory properties of polyphenols underscore their significance in the management of cardiovascular diseases. In recent years, particular attention has been paid to the impact of resveratrol on cardiovascular diseases. Conclusions. The cited studies have demonstrated that polyphenols, including resveratrol, may have a significant impact on reducing the incidence of selected cardiovascular diseases, decreasing mortality, and alleviating disease progression. However, further research in this area is undoubtedly necessary.
Bibliografia
1. World Health Organization: The top 10 causes of death; http://www.who.int/news-room/fact-sheets/detail/the-top-10causes-of-death (accessed 02.04.2024).
2. Statistics Poland: Mortality in 2021. Deaths by cause – preliminary data; http://stat.gov.pl/obszary-tematyczne/ludnosc/ statystyka-przyczyn-zgonow/umieralnosc-w-2021-rokuzgony-wedlug-przyczyn-dane-wstepne,10,3.html (accessed 02.04.2024).
3. Bojdo P., Gąsiorkiewicz B., Koczurkiewcz-Adamczyk P. et al.: The role of oxidative stress in the etiology of selected civilization diseases. Farm Pol 2021; 77(2): 111-120. doi: 10.32383/farmpol/134797.
4. Tolva V., Mazzola S., Zerbi P. et al.: A successful experimental model for intimal hyperplasia prevention using a resveratrol-delivering balloon. J Vasc Surg 2016; 63(3): 788-794. doi: 10.1016/j.jvs.2014.09.035.
5. Sinkiewicz W.: Czerwone wino, procyjanidy, resweratrol i długowieczność. Kardiol Dypl 2010; 9(8): 95-98.
6. Chojnacka K., Laskowska J.: Polifenole w leczeniu nieswoistych chorób zapalnych jelit. Postepy Biochem 2020; 66(3): 256-262. doi: 10.18388/pb.2020_334.
7. Santos-Buelga C., González-Manzano S., González-Paramás A.M.: Wine, Polyphenols, and Mediterranean Diets. What Else Is There to Say? Molecules 2021; 26(18): 5537. doi: 10.3390/molecules26185537.
8. Raj P., Thandapilly S.J., Wigle J. et al.: A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure. Molecules 2021; 26(21): 6600. doi: 10.3390/molecules26216600.
9. Riba A., Deres L., Sumegi B. et al.: Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model. Oxid Med Cell Longev 2017; 2017: 6819281. doi: 10.1155/2017/6819281.
10. Aydın G., Erbaş O.: The effects of resveratrol on human health. FNG Demiroglu Bilim Tip Derg 2019; 5(4): 193-201. doi: 10.5606/fng.btd.2019.035.
11. Maciąg M., Nowak B.: Choroby cywilizacyjne i społeczne XXI w. – przegląd i badania. Lublin: Wydawnictwo Naukowe Tygiel; 2016.
12. Weiskirchen S., Weiskirchen R.: Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? Adv Nutr 2016; 7(4): 706-718. doi: 10.3945/an.115.011627.
13. LaHood A.J., Kok S.J.: Ethanol Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 32491313.
14. Zhao L., Meng X., Zhang Q.Y. et al.: A narrative review of prehypertension and the cardiovascular system: effects and potential pathogenic mechanisms. Ann Transl Med 2021; 9(2): 170. doi: 10.21037/atm-20-5482.
15. Liu Y., Ma W., Zhang P. et al.: Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clin Nutr 2015; 34(1): 27-34. doi: 10.1016/j.clnu.2014.03.009.
16. Fogacci F., Tocci G., Presta V. et al.: Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr 2019; 59(10): 1605-1618. doi: 10.1080/10408398.2017.1422480.
17. Yu D., Tang Z., Li B. et al.: Resveratrol against Cardiac Fibrosis: Research Progress in Experimental Animal Models. Molecules 2021; 26(22): 6860. doi: 10.3390/molecules26226860.
18. Dguzeh U., Haddad N.C., Smith K.T.S. et al.: Alcoholism: A Multi-Systemic Cellular Insult to Organs. Int J Environ Res Public Health 2018; 15(6): 1083. doi: 10.3390/ ijerph15061083.
19. Iyer R.P., Jung M., Lindsey M.L.: MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol 2016; 311(1): H190-H198. doi: 10.1152/ajpheart.00243.2016.
20. Wu H., Li G.N., Xie J. et al.: Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in STZ-induced diabetic mice. BMC Cardiovasc Disord 2016; 16: 5. doi: 10.1186/s12872-015-0169-z.
21. Kuno A., Hosoda R., Tsukamoto M. et al.: SIRT1 in the cardiomyocyte counteracts doxorubicin-induced cardiotoxicity via regulating histone H2AX. Cardiovasc Res 2023; 118(17): 3360-3373. doi: 10.1093/cvr/cvac026.
22. Frankenstein H., Robak J., Lewandowska U. et al.: Sirtuina 1 jako potencjalny cel molekularny resweratrolu w wybranych chorobach [Sirtuin 1 as a potential molecular target of resveratrol in selected diseases]. Postepy Biochem 2024; 69(4): 264-273. doi: 10.18388/pb.2021_499.
23. Hou C.Y., Chen Y.W., Hazeena S.H. et al.: Cardiovascular risk of dietary trimethylamine oxide precursors and the therapeutic potential of resveratrol and its derivatives. FEBS Open Bio 2024; 14(3): 358-379. doi: 10.1002/2211-5463.13762.
24. Kamann S., Haase T., Stolzenburg N. et al.: Resveratrol-Coated Balloon Catheters in Porcine Coronary and Peripheral Arteries. Int J Mol Sci 2019; 20(9): 2285. doi: 10.3390/ ijms20092285.
25. Kazemirad H., Kazerani H.R.: Cardioprotective effects of resveratrol following myocardial ischemia and reperfusion. Mol Biol Rep 2020; 47(8): 5843-5850. doi: 10.1007/s11033020-05653-7.
26. Chekalina N.I.: Resveratrol has a positive effect on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease. Wiad Lek 2017; 70(2 pt 2): 286-291.
27. Keramat S., Sharebiani H., Patel M. et al.: The Potential Role of Antioxidants in the Treatment of Peripheral Arterial Disease: A Systematic Review. Antioxidants (Basel) 2022; 11(11): 2126. doi: 10.3390/antiox11112126.
28. Fan D., Liu C., Guo Z. et al.: Resveratrol Promotes Angiogenesis in a FoxO1-Dependent Manner in Hind Limb Ischemia in Mice. Molecules 2021; 26(24): 7528. doi: 10.3390/molecules26247528.
29. McDermott M.M., Martens C.R., Domanchuk K.J. et al.: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 2024; 15(1): 5046. doi: 10.1038/s41467-024-49092-5.
30. Sperling M., Grzelak T., Czyżewska K.: Endokrynna funkcja tkanki tłuszczowej w ujęciu historycznym. Hygeia Public Health 2016; 51(4): 339-342.
31. Fortunato I.M., Dos Santos T.W., Ferraz L.F.C. et al.: Effect of Polyphenols Intake on Obesity-Induced Maternal Programming. Nutrients 2021; 13(7): 2390. doi: 10.3390/ nu13072390.
32. Dal-Pan A., Blanc S., Aujard F.: Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 2010; 10: 11. doi: 10.1186/1472-679310-11.
33. Li F., Gao C., Yan P. et al.: EGCG Reduces Obesity and White Adipose Tissue Gain Partly Through AMPK Activation in Mice. Front Pharmacol 2018; 9: 1366. doi: 10.3389/ fphar.2018.01366.
34. Forney L.A., Lenard N.R., Stewart L.K. et al.: Dietary Quercetin Attenuates Adipose Tissue Expansion and Inflammation and Alters Adipocyte Morphology in a Tissue-Specific Manner. Int J Mol Sci 2018; 19(3): 895. doi: 10.3390/ ijms19030895.
35. Nettore I.C., Rocca C., Mancino G. et al.: Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats. J Nutr Biochem 2019; 69: 151-162. doi: 10.1016/j.jnutbio.2019.03.019.
36. Arias N., Picó C., Macarulla M.T. et al.: A combination of resveratrol and quercetin induces browning in white adipose tissue of rats fed an obesogenic diet. Obesity (Silver Spring) 2017; 25(1): 111-121. doi: 10.1002/oby.21706.
37. Liu T.Y., Yu H.R., Tsai C.C. et al.: Resveratrol intake during pregnancy and lactation re-programs adiposity and ameliorates leptin resistance in male progeny induced by maternal high-fat/high sucrose plus postnatal high-fat/high sucrose diets via fat metabolism regulation. Lipids Health Dis 2020; 19(1): 174. doi: 10.1186/s12944-020-01349-w.
38. Błażejewska-Hyżorek B., Czernuszenko A., Członkowska A. et al.: Wytyczne postępowania w udarze mózgu. Pol Przegl Neurol 2019; 15: 1-155. doi: 10.5603/PPN.2019.0001.
39. Gibas K.: Choroby naczyniowe mózgu. In: Brzęk A., Krzystanek E., Siuda J., ed., Fizjoterapia i leczenie w wybranych jednostkach chorobowych w obrębie ośrodkowego układu nerwowego: rozważania teoretyczne i zalecenia praktyczne. Podręcznik dla studentów kierunków medycznych, w tym f izjoterapii i lekarskiego. Katowice: SUM; 2022. 15-22. doi: 10.47590/sum.9788375094534.
40. Sienkiewicz-Jarosz H.: Udar mózgu. Kompendium dla praktyka. Warszawa: PZWL; 2020.
41. Chen J., Bai Q., Zhao Z. et al.: Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. Acta Neurol Scand 2016; 134(1): 54-60. doi: 10.1111/ane.12511.
42. Abd Aziz W., Wani N.A., Iezhitsa I., Agarwal R. et al.: Neuroprotection by trans-resveratrol against collagenase-induced neurological and neurobehavioural deficits in rats involves adenosine A1 receptors. Neurol Res 2020; 42(3): 189-208. doi: 10.1080/01616412.2020.1716470.
43. Zhao R., Zhao K., Su H. et al.: Resveratrol ameliorates brain injury via the TGF-β-mediated ERK signaling pathway in a rat model of cerebral hemorrhage. Exp Ther Med 2019; 18(5): 3397-3404. doi: 10.3892/etm.2019.7939.
44. Bonsack F., Alleyne C.H. Jr., Sukumari-Ramesh S.: Resveratrol Attenuates Neurodegeneration and Improves Neurological Outcomes after Intracerebral Hemorrhage in Mice. Front Cell Neurosci 2017; 11: 228. doi: 10.3389/fncel.2017.00228.
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Na tych samych warunkach 4.0 Międzynarodowe.
Prawa autorskie (c) 2026 Review of Medical Practice